10.02
08-May-25 15:45:00
15 minutes delayed
Stocks
+0.53
+5.58%
Today's range
9.25 - 10.38
ISIN
N/A
Source
NASDAQ
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
31 Mar 2025 06:30:00 By Nasdaq GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
07 Feb 2025 07:00:00 By Nasdaq GlobeNewswire